Capitol Vein Blog

Thursday, July 7, 2011

New Medication to Prevent Blood Clots

You may have read about a new oral medication, Xarelto, used to reduce the risk of blood clots after joint replacement surgery.  It was just released after the company received FDA approval for this indication.  The FDA study conducted to approve Xarelto cited reduced risk of blood clots with this medication when compared to Lovenox or Coumadin.

Currently Warfarin (Coumadin) and Lovenox (given by injection) have been the mainstays of therapy to prevent blood clots after hip or knee replacement surgery, where the risk of deep vein thrombosis (DVT) is notably increased. We know that DVT is a risk factor for developing varicose veins.  Problems with Coumadin include frequent blood tests to monitor the appropriate level of the drug, and dosing adjustment on a frequent basis.  Lovenox requires injection.

While Xarelto is not widely used yet, due to recent approval, you may expect to see it replacing one of the other medications in the near future.


Post a Comment